Filtered By:
Condition: Heart Attack
Education: Study
Nutrition: Vitamins

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 407 results found since Jan 2013.

Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation Clinical Sciences
Conclusions—This meta-analysis confirms the main findings of the randomized controlled trials of dabigatran, rivaroxaban, and apixaban in the real-world setting and, hence, strengthens their validity.
Source: Stroke - August 28, 2017 Category: Neurology Authors: George Ntaios, Vasileios Papavasileiou, Konstantinos Makaritsis, Konstantinos Vemmos, Patrik Michel, Gregory Y.H. Lip Tags: Arrhythmias, Secondary Prevention, Meta Analysis, Mortality/Survival, Ischemic Stroke Original Contributions Source Type: research

Differential Effect of B-Vitamin Therapy by Antiplatelet Use on Risk of Recurrent Vascular Events After Stroke Brief Reports
Conclusions— High-dose B vitamin therapy may be associated with a higher risk of recurrent stroke among stroke survivors taking antiplatelets, but does not have a significant effect on recurrent stroke risk in those who are not on antiplatelets. Future randomized controlled trials may consider evaluating the effect of homocysteine lowering among stroke survivors with elevated homocysteine who are not on antiplatelet therapy.
Source: Stroke - February 23, 2015 Category: Neurology Authors: Arshi, B., Ovbiagele, B., Markovic, D., Saposnik, G., Towfighi, A. Tags: Secondary prevention, Antiplatelets, Endothelium/vascular type/nitric oxide Brief Reports Source Type: research

Shared genetic susceptibility of vascular-related biomarkers with ischemic and recurrent stroke
Conclusions: Our data identify a genetic contribution to inflammatory and hemostatic biomarkers in a stroke population. Additionally, our results suggest shared genetic contributions to circulating CRP levels measured poststroke and risk for incident and recurrent ischemic stroke. These data broaden our understanding of genetic contributors to biomarker variation and ischemic stroke risk, which should be useful in clinical risk evaluation.
Source: Neurology - January 25, 2016 Category: Neurology Authors: Williams, S. R., Hsu, F.-C., Keene, K. L., Chen, W.-M., Nelson, S., Southerland, A. M., Madden, E. B., Coull, B., Gogarten, S. M., Furie, K. L., Dzhivhuho, G., Rowles, J. L., Mehndiratta, P., Malik, R., Dupuis, J., Lin, H., Seshadri, S., Rich, S. S., Sale Tags: All Cerebrovascular disease/Stroke, Case control studies, Risk factors in epidemiology, All Genetics, Association studies in genetics ARTICLE Source Type: research

The China Stroke Secondary Prevention Trial (CSSPT) protocol: a double‐blinded, randomized, controlled trial of combined folic acid and B vitamins for secondary prevention of stroke
DiscussionThis is the first multicenter randomized trial of secondary prevention for ischemic stroke in a Chinese population with a higher homocysteine level but without folate food fortification.
Source: International Journal of Stroke - March 12, 2013 Category: Neurology Authors: Xuedong Liu, Ming Shi, Feng Xia, Junliang Han, Zhirong Liu, Bo Wang, Fang Yang, Li Li, Songdi Wu, Ling Wang, Nan Liu, Yali Lv, Gang Zhao Tags: Protocols Source Type: research

Folic acid, a B vitamin, lowers stroke risk in people with high blood pressure
If you’re among the one in three American adults with high blood pressure, be sure you’re getting plenty of the B vitamin known as folate. Doing so may lower your odds of having a stroke, an often disabling or deadly event linked to high blood pressure, a new study suggests. Folate occurs naturally in many foods, but especially green leafy vegetables, beans, and citrus fruits. Here in the United States, add to the list most grain products, including wheat flour, cornmeal, pasta, and rice. They are fortified with the synthetic version of folate, known as folic acid. That’s not the case in many countries ar...
Source: New Harvard Health Information - March 18, 2015 Category: Consumer Health News Authors: Julie Corliss Tags: Drugs and Supplements Hypertension and Stroke high blood pressure Source Type: news

Vitamin B may reduce risk of stroke
Researchers have uncovered evidence that suggests vitamin B supplements could help to reduce the risk of stroke, according to a study published in the journal Neurology. Vitamin B supplements are said to be beneficial for many health issues, including stress, anxiety, depression, dementia, Alzheimer's disease and heart disease. However, according to Xu Yuming of Zhengzhou University in Zhengzhou, China, previous studies have conflicting findings regarding the use of vitamin B supplements and stroke or heart attack...
Source: Health News from Medical News Today - September 19, 2013 Category: Consumer Health News Tags: Stroke Source Type: news

Restarting Anticoagulant Therapy After Intracranial Hemorrhage Clinical Sciences
Background and Purpose—The safety and efficacy of restarting anticoagulation therapy after intracranial hemorrhage (ICH) remain unclear. We performed a systematic review and meta-analysis to summarize the associations of anticoagulation resumption with the subsequent risk of ICH recurrence and thromboembolism.Methods—We searched published medical literature to identify cohort studies involving adults with anticoagulation-associated ICH. Our predictor variable was resumption of anticoagulation. Outcome measures were thromboembolic events (stroke and myocardial infarction) and recurrence of ICH. After assessing study het...
Source: Stroke - May 22, 2017 Category: Neurology Authors: Santosh B. Murthy, Ajay Gupta, Alexander E. Merkler, Babak B. Navi, Pitchaiah Mandava, Costantino Iadecola, Kevin N. Sheth, Daniel F. Hanley, Wendy C. Ziai, Hooman Kamel Tags: Catheter Ablation and Implantable Cardioverter-Defibrillator, Myocardial Infarction, Intracranial Hemorrhage, Ischemic Stroke Original Contributions Source Type: research

0528 : Incidence and predictors of stroke among patients with chronic heart failure
Conclusion In our study, it seems that femal patients were at lower risk of stroke, in the other hand, prior history of myocardial fraction was predictor of stroke; however the severity of left ventricule systolic dysfunction did not influence the risk of embolic events. The author hereby declares no conflict of interest
Source: Archives of Cardiovascular Diseases Supplements - June 15, 2016 Category: Cardiology Source Type: research

Vitamin E supplementation (alone or with other antioxidants) and stroke: a meta-analysis
CONCLUSIONS: Supplementation with vitamin E alone is not associated with stroke reduction. Instead, supplementation of vitamin E with other antioxidants reduces the incidence of ischemic stroke but increases the risk of hemorrhagic stroke, cancelling any beneficial effect derived. Thus, vitamin E is not recommended in stroke prevention.SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration no. CRD42022258259.PMID:37698992 | DOI:10.1093/nutrit/nuad114
Source: Atherosclerosis - September 12, 2023 Category: Cardiology Authors: Enrico Maggio Valeria Proietti Bocchini Roberto Carnevale Pasquale Pignatelli Francesco Violi Lorenzo Loffredo Source Type: research

Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: The AMADEUS study.
CONCLUSION We have developed and validated 2 novel composite scores for stroke/thromboembolism/ bleeding that offer good discriminatory and predictive performance. However, these composite risk scores did not perform better than the easier and more practical 'traditional' stroke and bleeding risk scores that are currently in use, which allow greater practically and more personalised balancing of risks. PMID: 24009027 [PubMed - as supplied by publisher]
Source: Chest - September 5, 2013 Category: Respiratory Medicine Authors: Lip GY, Lane DA, Buller H, Apostolakis S Tags: Chest Source Type: research

Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation: Analysis From the ROCKET AF Trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)
Conclusions: In atrial fibrillation patients who temporarily or permanently discontinued anticoagulation, the risk of stroke or non-CNS embolism was similar with rivaroxaban or warfarin. An increased risk of stroke and non-CNS embolism was observed in rivaroxaban-treated patients compared with warfarin-treated patients after the end of the study, underscoring the importance of therapeutic anticoagulation coverage during such a transition.
Source: Journal of the American College of Cardiology - February 6, 2013 Category: Cardiology Authors: Manesh R. Patel, Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan P. Piccini, Zhongxin Zhang, Surya Mohanty, Daniel E. Singer, Werner Hacke, Günter Breithardt, Jonathan L. Halperin, Graeme J. Hankey, Richard C. Becker, Christopher C. Nessel, Scott D. Berkow Tags: Heart Rhythm Disorders Source Type: research

Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation Analysis From the ROCKET AF Trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)
ConclusionsIn atrial fibrillation patients who temporarily or permanently discontinued anticoagulation, the risk of stroke or non-CNS embolism was similar with rivaroxaban or warfarin. An increased risk of stroke and non-CNS embolism was observed in rivaroxaban-treated patients compared with warfarin-treated patients after the end of the study, underscoring the importance of therapeutic anticoagulation coverage during such a transition.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - February 4, 2013 Category: Cardiology Source Type: research

Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation.
CONCLUSIONS: Although our analysis was limited by the absence of head-to-head trials, based on the indirect comparison data available, our model projects that apixaban may be a cost-effective alternative to dabigatran 150 mg BID, dabigatran 110 mg BID, and rivaroxaban 20 mg once daily for stroke prevention in AF patients from the perspective of the United Kingdom National Health Services. PMID: 24508420 [PubMed - as supplied by publisher]
Source: Clinical Therapeutics - February 5, 2014 Category: Drugs & Pharmacology Authors: Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P Tags: Clin Ther Source Type: research

Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: GLORIA-AF Registry
Conclusions These global data confirm the sustained safety and effectiveness of dabigatran over 2years of follow-up, consistent with the results from clinical trials as well as contemporary real-world studies. WHAT IS KNOWN • Non- vitamin K antagonist (VKA) anticoagulants (NOACs) are the preferred therapy for prevention of ischemic stroke based on phase 3 trials, but there is insufficient information on their efficacy and safety in daily practice, based on prospectively collected data WHAT IS NEW • This study shows that in non-valvular AF patient population, with up to 2years of follow-up, the use of dabigatran led to ...
Source: American Heart Journal - September 1, 2017 Category: Cardiology Source Type: research